Swedish Orphan Biovitrum
kr 440.40Change from previous close: +0.87%Absolute change: +kr 3.80
At a glance
- Revenue growth
- +8.50%
- 2025 vs 2024
- Net income growth
- −87.70%
- 2025 vs 2024
- Net margin
- 1.7%
- 2024: 14.9%
Financial data
Amounts in millions of SEK; per-share values in SEK; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 28,238 | 26,027 | 22,123 | 18,790 | 15,529 |
| Cost of revenue | 5,967 | 5,717 | 4,963 | 4,413 | 3,484 |
| Gross profit | 22,271 | 20,310 | 17,160 | 14,377 | 12,045 |
| Selling, general and administrative | 10,973 | 10,967 | 9,773 | 7,637 | 6,294 |
| Research and development | 3,249 | 3,529 | 2,743 | 2,252 | 1,987 |
| Operating income | 8,058 | 5,823 | 4,653 | 4,520 | 3,794 |
| EBIT | 8,058 | 5,823 | 4,653 | 4,520 | 3,794 |
| EBITDA | 11,362 | 9,282 | 7,537 | 6,593 | 5,604 |
| Interest expense | 802 | 1,239 | 1,111 | 458 | 419 |
| Pre-tax income | 34.0 | 4,407 | 2,955 | 3,321 | 3,295 |
| Income tax | -442 | 528 | 546 | 683 | 616 |
| Net income | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
| Net income to common shareholders | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
| Basic EPS | 1.39 | 11.37 | 7.47 | 8.92 | 9.08 |
| Diluted EPS | 1.37 | 11.24 | 7.39 | 8.84 | 9.03 |
| Average shares (basic) | 344 | 342 | 323 | 296 | 295 |
| Average shares (diluted) | 348 | 346 | 326 | 298 | 297 |